BioNTech reported full-year 2025 revenue of €2.9 billion and a net loss of €1.1 billion while maintaining a strong financial position with €17.2 billion in cash and investments. The company expects 2026 revenue of €2.0–€2.3 billion and plans significant R&D spending as it advances its oncology pipeline, including immunomodulators, antibody-drug conjugates and mRNA cancer therapies. BioNTech anticipates a catalyst-rich year in 2026 with six late-stage clinical data readouts and continued progress toward its goal of becoming a multi-product biopharmaceutical company by 2030.
Source: Globe Newswire